RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
Authors:
Open Access
- 17 April 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Abstract
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year-old man with pancreatic cancer harboring TRIM33-RET fusion who responded remarkably to pralsetinib despite being intolerant to chemotherapy. To our knowledge, this is the first report on the clinical value of a single TRIM33-RET fusion in pancreatic cancer, which may benefit from the targeted therapy.Keywords
This publication has 24 references indexed in Scilit:
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerNew England Journal of Medicine, 2019
- Larotrectinib: First Global ApprovalDrugs, 2019
- Chemotherapy in Pancreatic Cancer: A Systematic ReviewMedicina, 2018
- Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registriesThe Lancet Global Health, 2018
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 PatientsClinical Cancer Research, 2017
- Pancreatic cancerThe Lancet, 2016
- Current status and progress of pancreatic cancer in ChinaWorld Journal of Gastroenterology, 2015
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung AdenocarcinomasCancer Discovery, 2013
- Structure and Physiology of the RET Receptor Tyrosine KinaseCold Spring Harbor Perspectives in Biology, 2013
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 StudyJournal of Clinical Oncology, 2010